A study led by researchers from the London School of Hygiene & Tropical Medicine found that interventions against respiratory syncytial virus (RSV) may be more cost-effective than previously estimated as findings showed that the disease burden is highly concentrated in the first 6 months of life in Kenya and South Africa, which is the window where a maternal vaccine or mAB would have their effect (recent phase 3 clinical studies show ~80% efficacy). The incidence of disease among infants younger than 6 months of age in these countries is higher than earlier projections from community incidence-based meta-analyses of low- and middle- income country data.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.